Positive Outlook on Penumbra’s Stock Driven by Ruby XL’s Market Impact and Efficiency Gains

Bank of America Securities analyst Travis Steed maintained a Buy rating on Penumbra yesterday and set a price target of $320.00.

Travis Steed has given his Buy rating due to a combination of factors surrounding Penumbra’s new Ruby XL product. The product’s introduction is expected to significantly increase Penumbra’s market share in the coil and plug segment, as it offers advantages in terms of fewer coils needed and faster procedure times. This efficiency not only reduces costs but also enhances operational efficiency for hospitals, making it a compelling choice for doctors.
Moreover, the Ruby XL is particularly suited for specific procedures such as pelvic congestion and varicoceles, which require large volume and length, thereby addressing a substantial portion of the market. The product’s ability to streamline procedures without expanding the overall market size or patient base further solidifies its value proposition. These factors, combined with a favorable price objective and market valuation, underpin Steed’s positive outlook on Penumbra’s stock.

In another report released on September 2, Evercore ISI also initiated coverage with a Buy rating on the stock with a $300.00 price target.